Cancer Panel Genetic Testing Service

Sequenom has developed four cancer gene panels: three rather general panels ("OncoCarta" v1.0; v2.0; v3.0), and one specific melanoma panel ("MelaCarta" v1.0). For example, the OncoCarta v1.0 Panel is based on 238 oncogene mutations across 19 common oncogenes (e.g. EGFR, ERBB2, BRAF; for a complete list of genes and mutations, please click here). OncoCarta Panels v2.0 and 3.0 test for an additional 152 and 218 mutations, resp. The MelaCarta v1.0 Panel screens for 72 mutations in 20 genes known to be involved in pathogenesis of melanoma.

Tumor samples from fresh, frozen or formalin-fixed paraffin embedded (FFPE) tissue can be used. Only non-synonymous coding mutations previously reported to occur as somatic mutations in human cancers were selected for the OncoCarta™ Panels. The main advantages of these genetic testing panels are:

• High sensitivity: mutations occuring at less than 10% frequency can be detected and reliably quantitated.
• DNA from FFPE tissue works well.
• Only 500 nanograms of genomic DNA are required per sample.

• ATLAS Biolabs’ team disposes of longstanding experience with various SNP genotyping technologies.
• Our service is fast and extremely reliable.
• ATLAS Biolabs is certified according to the international standards ISO 9001:2008 and ISO 13485.

• Customer sends DNA: 500 nanograms/sample.
• Sample processing: locus-specific PCR, single-base primer extension, chip spotting, mass spectrometry.
• Data analysis with Typer™ software (Sequenom).
• Generation of OncoCarta Panel Screening Service Report.

ATLAS Biolabs is certified according to the international standards ISO 9001:2008 and ISO 13485. Our processes are subject to rigorous quality control at all steps.

• ATLAS Biolabs runs a positive and a negative control in each sample plate.
• All quality assurance procedures are electronically documented and available for our customers on demand.